{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T00:08:56Z","timestamp":1759882136914,"version":"build-2065373602"},"reference-count":149,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,5,21]],"date-time":"2019-05-21T00:00:00Z","timestamp":1558396800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista de Gastroenterolog\u00eda de M\u00e9xico"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.rgmx.2019.04.002","type":"journal-article","created":{"date-parts":[[2019,6,22]],"date-time":"2019-06-22T16:32:50Z","timestamp":1561221170000},"page":"344-356","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["La b\u00fasqueda del Grial: una carrera por la supresi\u00f3n \u00e1cida"],"prefix":"10.1016","volume":"84","author":[{"given":"S.","family":"Sobrino-Coss\u00edo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Teramoto-Matsubara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Mateos-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.M.","family":"Abdo-Francis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Tawil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Olgu\u00edn-Ram\u00edrez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Orozco-Gamiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.S.","family":"Galvis-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.rgmx.2019.04.002_bib0750","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1365-2036.1995.tb00778.x","article-title":"The role and limitations of H2-receptor antagonists in the treatment of gastro-oesophageal reflux disease","volume":"9","author":"Colin-Jones","year":"1995","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.rgmx.2019.04.002_bib0755","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/290159a0","article-title":"Substituted benzimidazoles inhibit gastric acid secretion by blocking (H++ K+) ATPase","volume":"290","author":"Fellenius","year":"1981","journal-title":"Nature"},{"key":"10.1016\/j.rgmx.2019.04.002_bib0760","first-page":"77","article-title":"Gastric antisecretory effects of H83\/69, a benzimidazolyl-pyridyl-methyl-sulfoxide","volume":"4","author":"Sundell","year":"1977","journal-title":"Acta Pharmacol Toxicol"},{"key":"10.1016\/j.rgmx.2019.04.002_bib0765","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/med.2610100102","article-title":"Omeprazole: The first proton pump inhibitor","volume":"10","author":"Lindberg","year":"1990","journal-title":"Med Res Rev"},{"key":"10.1016\/j.rgmx.2019.04.002_bib0770","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1136\/gut.47.2.316","article-title":"Proton pump inhibitors","volume":"47","author":"Parsons","year":"2000","journal-title":"Gut"},{"key":"10.1016\/j.rgmx.2019.04.002_bib0775","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s00424-008-0495-4","article-title":"The gastric HK-ATPase: Structure, function, and inhibition","volume":"457","author":"Shin","year":"2008","journal-title":"Eur J Physiol"},{"key":"10.1016\/j.rgmx.2019.04.002_bib0780","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1345\/aph.1K246","article-title":"Stability of partial doses of omeprazole-sodium bicarbonate oral suspension","volume":"41","author":"Johnson","year":"2007","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.rgmx.2019.04.002_bib0785","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1111\/j.1365-2036.2009.03984.x","article-title":"Review article: Dual delayed release formulation of dexlansoprazole MR, a novel approach to overcome the limitations of conventional single release proton pump inhibitor therapy","volume":"29","author":"Metz","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.rgmx.2019.04.002_bib0790","unstructured":"Food and Drug Administration (FDA). FDA Drug Safety Podcast for Healthcare Professionals: Low magnesium levels can be associated with long-term use of Proton Pump Inhibitor drugs (PPIs) [actualizado 19 Ago 2013; consultado 18 Ago 2015]. Disponible en: http:\/\/www.fda.gov\/Drugs\/DrugSafety\/DrugSafetyPodcasts\/ucm245455.htm"},{"key":"10.1016\/j.rgmx.2019.04.002_bib0795","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/ajg.2018.29","article-title":"Discontinuing long-term PPI therapy: Why, with whom, and how?","volume":"113","author":"Targownik","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.rgmx.2019.04.002_bib0800","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1053\/j.gastro.2009.11.014","article-title":"Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss","volume":"138","author":"Targownik","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.rgmx.2019.04.002_bib0805","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/j.1365-2036.2012.05201.x","article-title":"Systematic review: Hypomagnesemia induced by proton pump inhibition","volume":"36","author":"Hess","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.rgmx.2019.04.002_bib0810","unstructured":"Food and Drug Administration. Information for healthcare professionals: update to the labeling of clopidogrel bisulfate (marketed as Plavix) to alert healthcare professionals about a drug interaction with omeprazole (marketed as Prilosec and Prilosec OTC). November 17, 2009 [consultado 19 Ago 2015]. Disponible en: https:\/\/www.pdr.net\/fda-drug-safety-communication\/plavix?druglabelid=525&id=5033"},{"key":"10.1016\/j.rgmx.2019.04.002_bib0815","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1001\/jamaneurol.2015.4791","article-title":"Association of proton pump inhibitors with risk of dementia: A pharmacoepidemiological claims data analysis","volume":"73","author":"Gomm","year":"2016","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.rgmx.2019.04.002_bib0820","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1053\/j.gastro.2017.05.046","article-title":"Association between proton pump inhibitor use and risk of progression of chronic kidney disease","volume":"153","author":"Klatte","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.rgmx.2019.04.002_bib0825","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1001\/jama.292.16.1955","article-title":"Risk of community acquired pneumonia and use of gastric acid-suppressive drugs","volume":"292","author":"Laheij","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.rgmx.2019.04.002_bib0830","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1053\/j.gastro.2017.04.047","article-title":"Complications of proton pump inhibitor therapy","volume":"153","author":"Vaezi","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.rgmx.2019.04.002_bib0835","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1111\/apt.14955","article-title":"Systematic review with meta-analysis: Risk of adverse cardiovascular events with proton pump inhibitors independent of clopidogrel","volume":"48","author":"Batchelor","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.rgmx.2019.04.002_bib0840","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/MOG.0000000000000471","article-title":"Adverse effects of proton pump inhibitors: Fact or fake news?","volume":"34","author":"Schubert","year":"2018","journal-title":"Curr Opin Gastroenterol"},{"key":"10.1016\/j.rgmx.2019.04.002_bib0845","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/ajg.2012.444","article-title":"Guidelines for the diagnosis and management of gastroesophageal reflux disease","volume":"108","author":"Katz","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.rgmx.2019.04.002_bib0850","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1566-0702(00)00215-0","article-title":"Functional and chemical anatomy of the afferent vagal system","volume":"85","author":"Berthoud","year":"2000","journal-title":"Auton Neurosci"},{"key":"10.1016\/j.rgmx.2019.04.002_bib0855","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1097\/MOG.0000000000000392","article-title":"Physiologic, pathophysiologic, and pharmacologic regulation of gastric acid secretion","volume":"33","author":"Schubert","year":"2017","journal-title":"Curr Opin Gastroenterol"},{"key":"10.1016\/j.rgmx.2019.04.002_bib0860","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/nrgastro.2012.32","article-title":"The enteric nervous system and neurogastroenterology","volume":"9","author":"Furness","year":"2012","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.rgmx.2019.04.002_bib0865","doi-asserted-by":"crossref","first-page":"C1","DOI":"10.1152\/ajpcell.00478.2009","article-title":"Revisiting the parietal cell","volume":"298","author":"Kopic","year":"2010","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1016\/j.rgmx.2019.04.002_bib0870","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1016\/j.bcp.2004.07.035","article-title":"Differences in binding properties of two proton pump inhibitors on the gastric H+, K+-ATPase in vivo","volume":"68","author":"Shin","year":"2004","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.rgmx.2019.04.002_bib0875","doi-asserted-by":"crossref","first-page":"25","DOI":"10.5056\/jnm.2013.19.1.25","article-title":"Pharmacokinetics and pharmacodynamics of the proton pump inhibitors","volume":"19","author":"Shin","year":"2013","journal-title":"J Neurogastroenterol Motil"},{"key":"10.1016\/j.rgmx.2019.04.002_bib0880","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/j.1749-6632.1991.tb27243.x","article-title":"Circadian dynamics of gastric acid secretion and pharmacodynamics of H2 receptor blockade","volume":"618","author":"Moore","year":"1991","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.rgmx.2019.04.002_bib0885","series-title":"Principles and Practice of Sleep Medicine","first-page":"312","article-title":"Gastrointestinal physiology in relation to sleep","author":"Orr","year":"2011"},{"key":"10.1016\/j.rgmx.2019.04.002_bib0890","doi-asserted-by":"crossref","first-page":"S226","DOI":"10.1097\/MCG.0b013e31803233b7","article-title":"The gastric H: K ATPase as a drug target: Past, present, and future","volume":"4","author":"Sachs","year":"2007","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.rgmx.2019.04.002_bib0895","doi-asserted-by":"crossref","first-page":"25","DOI":"10.5056\/jnm.2013.19.1.25","article-title":"Pharmacokinetics and pharmacodynamics of the proton pump inhibitors","volume":"19","author":"Shin","year":"2013","journal-title":"J Neurogastroenterol Motil"},{"key":"10.1016\/j.rgmx.2019.04.002_bib0900","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1365-2036.2006.02943.x","article-title":"Review article: the clinical pharmacology of proton pump inhibitors","volume":"23","author":"Sachs","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.rgmx.2019.04.002_bib0905","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1080\/17425255.2018.1461835","article-title":"Proton pump inhibitors: From CYP2C19 pharmacogenetics to precision medicine","volume":"14","author":"El Rouby","year":"2018","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.rgmx.2019.04.002_bib0910","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1007\/s11894-008-0098-4","article-title":"Pharmacology of proton pump inhibitors","volume":"10","author":"Shin","year":"2008","journal-title":"Curr Gastroenterol Rep"},{"key":"10.1016\/j.rgmx.2019.04.002_bib0915","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1586\/ecp.09.33","article-title":"Long lasting inhibitors of the gastric H, K-ATPase","volume":"2","author":"Shin","year":"2009","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.rgmx.2019.04.002_bib0920","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1053\/bega.2001.0184","article-title":"Pharmacological and pharmacodynamic essentials of H(2)-receptor antagonists and proton pump inhibitors for the practising physician","volume":"15","author":"Huang","year":"2001","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"10.1016\/j.rgmx.2019.04.002_bib0925","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1146\/annurev.pa.35.040195.001425","article-title":"The pharmacology of the gastric acid pump: The H+, K+ ATPase","volume":"35","author":"Sachs","year":"1995","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.rgmx.2019.04.002_bib0930","doi-asserted-by":"crossref","first-page":"7800","DOI":"10.1021\/ja049607w","article-title":"Chemistry of covalent inhibition of the gastric (H+, K+)-ATPase by proton pump inhibitors","volume":"126","author":"Shin","year":"2004","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.rgmx.2019.04.002_bib0935","doi-asserted-by":"crossref","first-page":"873","DOI":"10.2217\/pgs.11.4","article-title":"Update on the pharmacogenomics of proton pump inhibitors","volume":"12","author":"Hagym\u00e1si","year":"2011","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.rgmx.2019.04.002_bib0940","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1159\/000028183","article-title":"Differences in pH-dependent activation rates of substituted benzimidazoles and biological in vitro correlates","volume":"56","author":"Kromer","year":"1998","journal-title":"Pharmacology"},{"key":"10.1016\/j.rgmx.2019.04.002_bib0945","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s40272-013-0012-x","article-title":"Proton pump inhibitors in pediatrics: Mechanism of action, pharmacokinetics, pharmacogenetics, and pharmacodynamics","volume":"15","author":"Ward","year":"2013","journal-title":"Paediatr Drugs"},{"key":"10.1016\/j.rgmx.2019.04.002_bib0950","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/j.1875-9114.1997.tb03675.x","article-title":"Proton pump inhibitors and acid-related diseases","volume":"17","author":"Sachs","year":"1997","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.rgmx.2019.04.002_bib0955","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/0006-291X(85)90573-X","article-title":"Irreversible inactivation of rat gastric (H+-K+)-ATPase in vivo by omeprazole","volume":"126","author":"Im","year":"1985","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.rgmx.2019.04.002_bib0960","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1053\/gast.2002.36593","article-title":"Restoration of acid secretion following treatment with proton pump inhibitors","volume":"123","author":"Shin","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.rgmx.2019.04.002_bib0965","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/BF03189822","article-title":"Comparative pharmacokinetic\/pharmacodynamic analysis of proton pump inhibitors omeprazole, lansoprazole and pantoprazole, in humans","volume":"23","author":"Katashima","year":"1998","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"10.1016\/j.rgmx.2019.04.002_bib0970","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1021\/jm00158a001","article-title":"The mechanism of action of the gastric acid secretion inhibitor omeprazole","volume":"29","author":"Lindberg","year":"1986","journal-title":"J Med Chem"},{"key":"10.1016\/j.rgmx.2019.04.002_bib0975","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/0016-5085(95)90571-5","article-title":"Turnover of the gastric H+, K+-adenosine triphosphatase a subunit and its effect on inhibition of rat gastric acid secretion","volume":"109","author":"Gedda","year":"1995","journal-title":"Gastroenterology"},{"key":"10.1016\/j.rgmx.2019.04.002_bib0980","series-title":"Neurofarmacolog\u00eda fundamental y cl\u00ednica","first-page":"63","article-title":"Principios de farmacocin\u00e9tica cl\u00ednica","author":"Armijo","year":"1983"},{"year":"1992","series-title":"Applied Pharmacokinetics: Principles of Therapeutic Drug Monitoring","author":"Evans","key":"10.1016\/j.rgmx.2019.04.002_bib0985"},{"key":"10.1016\/j.rgmx.2019.04.002_bib0990","doi-asserted-by":"crossref","first-page":"429","DOI":"10.2165\/00003088-199120060-00001","article-title":"Nonlinear pharmacokinetics: Clinical implications","volume":"20","author":"Ludden","year":"1991","journal-title":"Clin Pharmacokin"},{"year":"1983","series-title":"Farmacocin\u00e9tica cl\u00ednica","author":"Wagner","key":"10.1016\/j.rgmx.2019.04.002_bib0995"},{"key":"10.1016\/j.rgmx.2019.04.002_bib1000","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1517\/17425247.2013.763792","article-title":"An update on pharmaceutical film coating for drug delivery","volume":"10","author":"Felton","year":"2013","journal-title":"Expert Opin Drug Deliv"},{"key":"10.1016\/j.rgmx.2019.04.002_bib1005","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.clinthera.2007.03.014","article-title":"A new esomeprazole packet (sachet) formulation for suspension: In vitro characteristics and comparative pharmacokinetics versus intact capsules\/tablets in healthy volunteers","volume":"4","author":"Bladh","year":"2007","journal-title":"Clin Ther."},{"key":"10.1016\/j.rgmx.2019.04.002_bib1010","first-page":"41","article-title":"Coating polymers for colon specific drug delivery: A comparative in vitro evaluation","volume":"53","author":"Sinha","year":"2003","journal-title":"Acta Pharm"},{"key":"10.1016\/j.rgmx.2019.04.002_bib1015","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0928-0987(98)00032-3","article-title":"Enteric polymers as binders and coating materials in multiple-unit site-specific drug delivery systems","volume":"7","author":"Marvola","year":"1999","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.rgmx.2019.04.002_bib1020","unstructured":"Food and Drug Administration (2009). Drugs, Dosage Form [consultado 6 Jul 2009]. Disponible en: http:\/\/www.fda.gov\/Drugs\/DevelopmentApprovalProcess\/FormsSubmissionRequirements\/ElectronicSubmissions\/Data-Standards Manualmonographs\/ucm071666.htm"},{"key":"10.1016\/j.rgmx.2019.04.002_bib1025","doi-asserted-by":"crossref","first-page":"180","DOI":"10.3109\/03639040903468811","article-title":"Delayed release film coating applications on oral solid dosage forms of proton pump inhibitors: Case studies","volume":"36","author":"Missaghi","year":"2010","journal-title":"Drug Dev Ind Pharm"},{"key":"10.1016\/j.rgmx.2019.04.002_bib1030","doi-asserted-by":"crossref","first-page":"27","DOI":"10.5009\/gnl15502","article-title":"25 years of proton pump inhibitors: A comprehensive review","volume":"11","author":"Strand","year":"2017","journal-title":"Gut Liver"},{"key":"10.1016\/j.rgmx.2019.04.002_bib1035","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1006\/phrs.2000.0719","article-title":"Area under the curve and bioavailability","volume":"42","author":"Rescigno","year":"2000","journal-title":"Pharm Res"},{"key":"10.1016\/j.rgmx.2019.04.002_bib1040","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s00228-002-0502-1","article-title":"The effect of the area under the plasma concentration vs time curve and the maximum plasma concentration of esomeprazole on intragastric pH","volume":"58","author":"Junghard","year":"2002","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.rgmx.2019.04.002_bib1045","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/ajg.2012.444","article-title":"Guidelines for the diagnosis and management of gastroesophageal reflux disease","volume":"108","author":"Katz","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.rgmx.2019.04.002_bib1050","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1111\/j.1572-0241.2006.00630.x","article-title":"The Montreal definition and classification of gastroesophageal reflux disease: A global evidence-based consensus","volume":"101","author":"Vakil","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.rgmx.2019.04.002_bib1055","doi-asserted-by":"crossref","first-page":"518","DOI":"10.7326\/0003-4819-140-7-200404060-00011","article-title":"Short-term treatment with proton-pump inhibitors as a test for gastroesophageal reflux disease: A meta-analysis of diagnostic test characteristics","volume":"140","author":"Numans","year":"2004","journal-title":"Ann Intern Med."},{"key":"10.1016\/j.rgmx.2019.04.002_bib1060","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.cgh.2011.11.018","article-title":"Acid suppression for reflux disease: \u2018off-the-peg\u2019 or a tailored approach?","volume":"10","author":"Hunt","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.rgmx.2019.04.002_bib1065","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/j.1365-2036.2010.04550.x","article-title":"Weakly acidic refluxes have a major role in the pathogenesis of proton pump inhibitor-resistant reflux oesophagitis","volume":"33","author":"Frazzoni","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.rgmx.2019.04.002_bib1070","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD002095.pub5","article-title":"Short-term treatment with proton pump inhibitors. H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease","author":"Sigterman","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.rgmx.2019.04.002_bib1075","article-title":"Medical treatments in the short term management of reflux oesophagitis","author":"Khan","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.rgmx.2019.04.002_bib1080","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1111\/j.1365-2982.2012.01888.x","article-title":"PPI therapy is equally effective in well-defined non-erosive reflux disease and in reflux esophagitis: A meta-analysis","volume":"24","author":"Weijenborg","year":"2012","journal-title":"Neurogastroenterol Motil."},{"key":"10.1016\/j.rgmx.2019.04.002_bib1085","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/s11894-017-0586-5","article-title":"Proton pump inhibitors in gastroesophageal reflux disease: Friend or foe","volume":"19","author":"Gyawali","year":"2017","journal-title":"Curr Gastroenterol Rep"},{"key":"10.1016\/j.rgmx.2019.04.002_bib1090","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD002095.pub4","article-title":"Short-term treatment with proton pump inhibitors H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease","volume":"11","author":"Van Pixteren","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.rgmx.2019.04.002_bib1095","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/S1542-3565(04)00288-5","article-title":"Effectiveness of proton pump inhibitors in nonerosive reflux disease","volume":"2","author":"Dean","year":"2004","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.rgmx.2019.04.002_bib1100","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1046\/j.1365-2036.2001.01128.x","article-title":"Systematic review of proton pump inhibitors for the acute treatment of reflux oesophagitis","volume":"15","author":"Edwards","year":"2001","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.rgmx.2019.04.002_bib1105","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1111\/j.1572-0241.2001.03600.x","article-title":"Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: A randomized controlled trial","volume":"96","author":"Richter","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.rgmx.2019.04.002_bib1110","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1016\/j.cgh.2006.09.013","article-title":"Esomeprazole versus other proton pump inhibitors in erosive esophagitis: A meta-analysis of randomized clinical trials","volume":"4","author":"Gralnek","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.rgmx.2019.04.002_bib1115","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.3748\/wjg.v16.i30.3750","article-title":"Advances in diagnostic testing for gastroesophageal reflux disease","volume":"16","author":"Gawron","year":"2010","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.rgmx.2019.04.002_bib1120","doi-asserted-by":"crossref","first-page":"24S-49S","DOI":"10.1007\/BF02214870","article-title":"Optimizing acid suppression for treatment of acid-related diseases","volume":"40","author":"Hunt","year":"1995","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.rgmx.2019.04.002_bib1125","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1007\/s10620-014-3324-y","article-title":"Dual ambulatory pH monitoring in patients with gastroesophageal reflux rendered asymptomatic with proton pump inhibitor therapy","volume":"60","author":"Lin","year":"2015","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.rgmx.2019.04.002_bib1130","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1136\/gut.2007.130104","article-title":"Presence of gas in the refluxate enhances reflux perception in non-erosive patients with physiological acid exposure of the oesophagus","volume":"57","author":"Emerenziani","year":"2008","journal-title":"Gut"},{"key":"10.1016\/j.rgmx.2019.04.002_bib1135","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/S0016-5085(98)70014-9","article-title":"Differential effect of long-term esophageal acid exposure on mechano-sensitivity and chemosensitivity in humans","volume":"115","author":"Fass","year":"1998","journal-title":"Gastroenterology"},{"key":"10.1016\/j.rgmx.2019.04.002_bib1140","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1136\/gut.2005.074690","article-title":"Determinants of perception of heartburn and regurgitation","volume":"55","author":"Bredenoord","year":"2006","journal-title":"Gut"},{"key":"10.1016\/j.rgmx.2019.04.002_bib1145","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1136\/gut.2007.145581","article-title":"Management of heartburn not responding to proton pump inhibitors","volume":"58","author":"Fass","year":"2009","journal-title":"Gut"},{"key":"10.1016\/j.rgmx.2019.04.002_bib1150","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/nrgastro.2013.50","article-title":"NERD: An umbrella term including heterogeneous subpopulations","volume":"10","author":"Savarino","year":"2013","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.rgmx.2019.04.002_bib1155","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1111\/j.1365-2982.2008.01122.x","article-title":"Oesophageal afferent pathway sensitivity in non-erosive reflux disease","volume":"20","author":"Hobson","year":"2008","journal-title":"Neurogastroenterol Motil"},{"key":"10.1016\/j.rgmx.2019.04.002_bib1160","first-page":"178","article-title":"Functional esophageal disorders","author":"Aziz","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.rgmx.2019.04.002_bib1165","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1111\/nmo.12864","article-title":"Esophageal acid sensitivity and mucosal integrity in patients with functional heartburn","volume":"28","author":"Weijenborg","year":"2016","journal-title":"Neurogastroenterol Motil"},{"key":"10.1016\/j.rgmx.2019.04.002_bib1170","first-page":"325","article-title":"Twenty four-hour pH monitoring of the distal esophagus. A quantitative measure of gastroesophageal reflux","volume":"62","author":"Johnson","year":"1974","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.rgmx.2019.04.002_bib1175","doi-asserted-by":"crossref","first-page":"497","DOI":"10.5056\/jnm14038","article-title":"Diagnostic utility of impedance-pH monitoring in refractory non-erosive reflux disease","volume":"20","author":"Khan","year":"2014","journal-title":"J Neurogastroenterol Motil"},{"key":"10.1016\/j.rgmx.2019.04.002_bib1180","series-title":"Handbook of Gastrointestinal Motility and Functional Disorders","first-page":"77","article-title":"Esophageal hypersensitivity","author":"Remes-Troche","year":"2015"},{"key":"10.1016\/j.rgmx.2019.04.002_bib1185","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/j.1365-2982.2006.00787.x","article-title":"Non-cardiac chest pain: An update","volume":"18","author":"Fass","year":"2006","journal-title":"Neurogastroenterol Motil"},{"key":"10.1016\/j.rgmx.2019.04.002_bib1190","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1111\/nmo.12339","article-title":"The role of pain modulators in esophageal disorders \u2014 no pain no gain","volume":"26","author":"Dickman","year":"2014","journal-title":"Neurogastroenterol Motil"},{"key":"10.1016\/j.rgmx.2019.04.002_bib1195","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1136\/gut.2007.145581","article-title":"Management of heartburn not responding to proton pump inhibitors","volume":"58","author":"Fass","year":"2009","journal-title":"Gut"},{"key":"10.1016\/j.rgmx.2019.04.002_bib1200","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.cellbi.2008.09.007","article-title":"Diversity of tight junctions (TJs) between gastrointestinal epithelial cells and their function in maintaining the mucosal barrier","volume":"33","author":"Yu","year":"2009","journal-title":"Cell Biol Int"},{"key":"10.1016\/j.rgmx.2019.04.002_bib1205","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.cgh.2012.01.022","article-title":"Regurgitation is less responsive to acid suppression than heartburn in patients with gastroesophageal reflux disease","volume":"10","author":"Kahrilas","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.rgmx.2019.04.002_bib1210","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1038\/ajg.2011.146","article-title":"Response of regurgitation to proton pump inhibitor therapy in clinical trials of gastroesophageal reflux disease","volume":"106","author":"Kahrilas","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.rgmx.2019.04.002_bib1215","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1136\/gut.2011.241307","article-title":"Response of unexplained chest pain to proton pump inhibitor treatment in patients with and without objective evidence of gastro-oesophageal reflux disease","volume":"60","author":"Kahrilas","year":"2011","journal-title":"Gut"},{"key":"10.1016\/j.rgmx.2019.04.002_bib1220","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1111\/j.1572-0241.2005.41657.x","article-title":"Diagnostic and therapeutic use of proton pump inhibitors in non-cardiac chest pain: A metaanalysis","volume":"100","author":"Cremonini","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.rgmx.2019.04.002_bib1225","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1001\/archinte.165.11.1222","article-title":"Is proton pump inhibitor testing an effective approach to diagnose gastroesophageal reflux disease in patients with noncardiac chest pain? A meta-analysis","volume":"165","author":"Wang","year":"2005","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.rgmx.2019.04.002_bib1230","first-page":"CD004823","article-title":"Gastro-oesophageal reflux treatment for prolonged non-specific cough in children and adults","author":"Chang","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.rgmx.2019.04.002_bib1235","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/MCG.0b013e3181b8e97b","article-title":"Long-term therapeutic outcome of patients undergoing ambulatory pH monitoring for chronic unexplained cough","volume":"44","author":"Hersh","year":"2010","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.rgmx.2019.04.002_bib1240","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1111\/j.1440-1746.2004.03589.x","article-title":"Extraesophageal and atypical manifestations of GERD","volume":"19","author":"Wong","year":"2004","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.rgmx.2019.04.002_bib1245","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1007\/s11894-013-0318-4","article-title":"Extra-esophageal manifestations of GERD: Who responds to GERD therapy?","volume":"15","author":"Naik","year":"2013","journal-title":"Curr Gastroenterol Rep"},{"key":"10.1016\/j.rgmx.2019.04.002_bib1250","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1111\/j.1572-0241.2004.40170.x","article-title":"The role of gastric and duodenal agents in laryngeal injury: An experimental canine model","volume":"99","author":"Adhami","year":"2004","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.rgmx.2019.04.002_bib1255","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1097\/01720610-200508000-00008","article-title":"Laryngopharyngeal reflux \u2014 It's not GERD","volume":"18","author":"Diamond","year":"2005","journal-title":"JAAPA"},{"key":"10.1016\/j.rgmx.2019.04.002_bib1260","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/01.mlg.0000192173.00498.ba","article-title":"Treatment of chronic posterior laryngitis with esomeprazole","volume":"116","author":"Vaezi","year":"2006","journal-title":"Laryngoscope"},{"key":"10.1016\/j.rgmx.2019.04.002_bib1265","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1111\/j.1572-0241.2006.00844.x","article-title":"Proton pump inhibitor therapy for suspected GERD-related chronic laryngitis: A meta-analysis of randomized controlled trials","volume":"101","author":"Qadeer","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.rgmx.2019.04.002_bib1270","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1164\/rccm.200507-1167OC","article-title":"Effects of esomeprazole 40mg twice daily on asthma: A randomized placebo-controlled trial","volume":"173","author":"Kiljander","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rgmx.2019.04.002_bib1275","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1056\/NEJMoa0806290","article-title":"Efficacy of esomeprazole for treatment of poorly controlled asthma","volume":"360","author":"Mastronarde","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rgmx.2019.04.002_bib1280","first-page":"CD011969","article-title":"Deprescribing versus continuation of chronic proton pump inhibitor use in adults","volume":"3","author":"Boghossian","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.rgmx.2019.04.002_bib1285","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/ajg.2009.556","article-title":"Efficacy of three different dosages of esomeprazole in the long-term management of reflux disease: A prospective, randomized study, using the wireless bravo pH system","volume":"105","author":"Vasiliadis","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.rgmx.2019.04.002_bib1290","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1572-0241.2001.03443.x","article-title":"Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: A randomized, double-blind, placebo controlled study of efficacy and safety","volume":"96","author":"Johnson","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.rgmx.2019.04.002_bib1295","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1053\/gast.2001.28649","article-title":"Step-down management of gastroesophageal reflux disease","volume":"121","author":"Inadomi","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.rgmx.2019.04.002_bib1300","doi-asserted-by":"crossref","first-page":"41021","DOI":"10.1038\/srep41021","article-title":"Effectiveness and tolerability of different recommended doses of PPIs and H2RAs in GERD: Network meta-analysis and GRADE system","volume":"7","author":"Zhang","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.rgmx.2019.04.002_bib1305","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1111\/j.1572-0241.1998.221_a.x","article-title":"Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors","volume":"93","author":"Peghini","year":"1998","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.rgmx.2019.04.002_bib1310","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1046\/j.1365-2036.1998.00419.x","article-title":"Gastro-esophageal reflux associated with nocturnal gastric acid breakthrough on proton pump inhibitors","volume":"12","author":"Katz","year":"1998","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.rgmx.2019.04.002_bib1315","doi-asserted-by":"crossref","first-page":"A17","DOI":"10.1016\/S0016-5085(00)82137-X","article-title":"A PPI is a PPI: Lessons learned from intragastric pH monitoring [abstract]","volume":"118","author":"Tutuian","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1016\/j.rgmx.2019.04.002_bib1320","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1111\/j.1365-2036.2004.01949.x","article-title":"Effect of splitting the dose of esomeprazole on gastric acidity and nocturnal acid breakthrough","volume":"19","author":"Hammer","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.rgmx.2019.04.002_bib1325","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1111\/j.1365-2036.2005.02432.x","article-title":"Intragastric acidity during treatment with esomeprazole 40mg twice daily or pantoprazole 40mg twice daily \u2014 a randomized, two-way crossover study","volume":"21","author":"Miehlke","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.rgmx.2019.04.002_bib1330","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/j.1365-2036.2004.02079.x","article-title":"Intragastric acid suppression and pharmacokinetics of twice-daily esomeprazole: A randomized, three-way crossover study","volume":"20","author":"Katz","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.rgmx.2019.04.002_bib1335","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1111\/j.1572-0241.2003.08783.x","article-title":"Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: A five-way crossover study","volume":"98","author":"Miner","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.rgmx.2019.04.002_bib1340","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/apt.12540","article-title":"Randomised clinical trial: Daily pantoprazole magnesium 40mg vs. esomeprazole 40mg for gastro-oesophageal reflux disease, assessed by endoscopy and symptoms","volume":"39","author":"Moraes-Filho","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.rgmx.2019.04.002_bib1345","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s40261-013-0135-4","article-title":"Efficacy, safety, and tolerability of pantoprazole magnesium in the treatment of reflux symptoms in patients with gastroesophageal reflux disease (GERD): A prospective, multicenter, post-marketing observational study","volume":"34","author":"Remes-Troche","year":"2014","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.rgmx.2019.04.002_bib1350","doi-asserted-by":"crossref","first-page":"64","DOI":"10.5056\/jnm.2014.20.1.64","volume":"20","author":"L\u00f3pez-Alvarenga","year":"2014","journal-title":"J Neurogastroenterol Motil"},{"key":"10.1016\/j.rgmx.2019.04.002_bib1355","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/(SICI)1520-636X(1997)9:1<17::AID-CHIR4>3.0.CO;2-D","article-title":"Differential stereoselective pharmacokinetics of pantoprazole, a proton pump inhibitor in extensive and poor metabolizers of pantoprazole \u2014 a preliminary study","volume":"9","author":"Tanaka","year":"1997","journal-title":"Chirality"},{"key":"10.1016\/j.rgmx.2019.04.002_bib1360","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1211\/0022357056361","article-title":"Pharmacodynamic comparison of pantoprazole enantiomers: inhibition of acid-related lesions and acid secretion in rats and guinea-pigs","volume":"57","author":"Cao","year":"2005","journal-title":"J Pharm Pharmacol"},{"key":"10.1016\/j.rgmx.2019.04.002_bib1365","doi-asserted-by":"crossref","first-page":"6017","DOI":"10.3748\/wjg.v12.i37.6017","article-title":"Comparative clinical trial of S-pantoprazole versus racemic pantoprazole in the treatment of gastro-esophageal reflux disease","volume":"12","author":"Pai","year":"2006","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.rgmx.2019.04.002_bib1370","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1007\/s10620-012-2297-y","article-title":"Efficacy of S-pantoprazole 20mg compared with pantoprazole 40mg in the treatment of reflux esophagitis: A randomized, double-blind comparative trial","volume":"57","author":"Cho","year":"2012","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.rgmx.2019.04.002_bib1375","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1023\/A:1016062508580","article-title":"Determination of R(+) and S(\u2212) lansoprazole using chiral stationary-phase liquid chromatography and their enantioselective pharmacokinetics in humans","volume":"13","author":"Katsuki","year":"1996","journal-title":"Pharm Res"},{"key":"10.1016\/j.rgmx.2019.04.002_bib1380","doi-asserted-by":"crossref","first-page":"366","DOI":"10.3109\/07853890.2011.554429","article-title":"Dexlansoprazole MR \u2014 A review","volume":"43","author":"Hershcovici","year":"2011","journal-title":"Ann Med"},{"key":"10.1016\/j.rgmx.2019.04.002_bib1385","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1365-2036.2005.02531.x","article-title":"Systematic review: Proton pump inhibitor failure in gastrooesophageal reflux disease \u2014 where next?","volume":"22","author":"Fass","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.rgmx.2019.04.002_bib1390","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1177\/1756283X16681701","article-title":"The role of dexlansoprazole modified release in the management of gastroesophageal reflux disease","volume":"10","author":"Fass","year":"2017","journal-title":"Ther Adv Gastroenterol"},{"key":"10.1016\/j.rgmx.2019.04.002_bib1395","doi-asserted-by":"crossref","first-page":"309","DOI":"10.5056\/jnm15105","article-title":"Unmet needs in the treatment of gastroesophageal reflux disease","volume":"21","author":"Dickman","year":"2015","journal-title":"J Neurogastroenterol Motil"},{"key":"10.1016\/j.rgmx.2019.04.002_bib1400","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1111\/j.1365-2036.2009.03933.x","article-title":"Clinical trials: Healing of erosive oesophagitis with dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed-release formulation-results from two randomized controlled studies","volume":"29","author":"Sharma","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.rgmx.2019.04.002_bib1405","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1111\/j.1365-2036.2009.03954.x","article-title":"Clinical trial: Dexlansoprazole MR, a proton pump inhibitor with dual delayed-release technology, effectively controls symptoms and prevents relapse in patients with healed erosive oesophagitis","volume":"29","author":"Metz","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.rgmx.2019.04.002_bib1410","doi-asserted-by":"crossref","first-page":"366","DOI":"10.3109\/07853890.2011.554429","article-title":"Dexlansoprazole: Dexlansoprazole MR \u2014 A review","volume":"43","author":"Hershcovici","year":"2011","journal-title":"Ann Med"},{"key":"10.1016\/j.rgmx.2019.04.002_bib1415","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1111\/j.1365-2036.2009.04119.x","article-title":"Clinical trial: Efficacy and safety of dexlansoprazole MR 60 and 90mg in healed erosive oesophagitis-maintenance of healing and symptom relief","volume":"30","author":"Howden","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.rgmx.2019.04.002_bib1420","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/apt.12349","article-title":"Indirect comparison of randomized controlled trials: comparative efficacy of dexlansoprazole vs. esomeprazole in the treatment of gastrooesophageal reflux disease","volume":"38","author":"Wu","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.rgmx.2019.04.002_bib1425","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1111\/j.1365-2036.2009.04013.x","article-title":"Clinical trial: The effects of the proton pump inhibitor dexlansoprazole MR on daytime and nighttime heartburn in patients with non-erosive reflux disease","volume":"29","author":"Fass","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.rgmx.2019.04.002_bib1430","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.cgh.2011.11.021","article-title":"Maintenance of heartburn relief after step-down from twice-daily proton pump inhibitor to once-daily dexlansoprazole modified release","volume":"10","author":"Fass","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.rgmx.2019.04.002_bib1435","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1111\/j.1572-0241.2003.07531.x","volume":"98","author":"Shaker","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.rgmx.2019.04.002_bib1440","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.gtc.2012.11.011","article-title":"Gastroesophageal reflux disease and sleep","volume":"42","author":"Fujiwara","year":"2013","journal-title":"Gastroenterol Clin North Am"},{"key":"10.1016\/j.rgmx.2019.04.002_bib1445","doi-asserted-by":"crossref","DOI":"10.1016\/S0016-5085(09)61970-3","volume":"136","author":"Morales-Arambula","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.rgmx.2019.04.002_bib1450","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/ajg.2010.458","article-title":"The effect of dexlansoprazole MR on nocturnal heartburn and GERD-related sleep disturbances in patients with symptomatic GERD","volume":"106","author":"Fass","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.rgmx.2019.04.002_bib1455","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1517\/17425255.2013.813018","article-title":"The pharmacokinetics of ilaprazole for gastro-esophageal reflux treatment","volume":"9","author":"de Bortoli","year":"2013","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.rgmx.2019.04.002_bib1460","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/j.1751-2980.2011.00557.x","article-title":"Acid inhibition effect of ilaprazole on Helicobacter pylori-negative healthy volunteers: An open randomized cross-over study","volume":"13","author":"Du","year":"2012","journal-title":"J Dig Dis"},{"key":"10.1016\/j.rgmx.2019.04.002_bib1465","doi-asserted-by":"crossref","first-page":"208","DOI":"10.5056\/jnm16087","article-title":"Esophageal acidification during nocturnal acid-breakthrough with ilaprazole versus omeprazole in gastroesophageal reflux disease","volume":"23","author":"Karyampudi","year":"2017","journal-title":"J Neurogastroenterol Motil"},{"key":"10.1016\/j.rgmx.2019.04.002_bib1470","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1007\/s40261-016-0446-3","article-title":"A randomized, double-blind, active-controlled, multi-center study of ilaprazole in the treatment of reflux esophagitis","volume":"36","author":"Xue","year":"2016","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.rgmx.2019.04.002_bib1475","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1111\/j.1365-2036.2004.01893.x","article-title":"Tenatoprazole, a novel proton pump inhibitor with a prolonged plasma half-life: Effects on intragastric pH and comparison with esomeprazole in healthy volunteers","volume":"19","author":"Galmiche","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.rgmx.2019.04.002_bib1480","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1111\/j.1572-0241.2005.41956.x","article-title":"Effect on intragastric pH of a PPI with a prolonged plasma half-life: Comparison between tenatoprazole and esomeprazole on the duration of acid suppression in healthy male volunteers","volume":"100","author":"Hunt","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.rgmx.2019.04.002_bib1485","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1124\/jpet.111.179556","article-title":"A study comparing the antisecretory effect of TAK-438, a novel potassium-competitive acid blocker, with lansoprazole in animals","volume":"337","author":"Hori","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.rgmx.2019.04.002_bib1490","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1111\/apt.13121","article-title":"Randomised clinical trial: Safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects","volume":"41","author":"Jenkins","year":"2015","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Revista de Gastroenterolog\u00eda de M\u00e9xico"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0375090619300722?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0375090619300722?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T04:46:43Z","timestamp":1759812403000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0375090619300722"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":149,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["S0375090619300722"],"URL":"https:\/\/doi.org\/10.1016\/j.rgmx.2019.04.002","relation":{},"ISSN":["0375-0906"],"issn-type":[{"type":"print","value":"0375-0906"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"La b\u00fasqueda del Grial: una carrera por la supresi\u00f3n \u00e1cida","name":"articletitle","label":"Article Title"},{"value":"Revista de Gastroenterolog\u00eda de M\u00e9xico","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rgmx.2019.04.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Asociaci\u00f3n Mexicana de Gastroenterolog\u00eda. Published by Masson Doyma M\u00e9xico S.A.","name":"copyright","label":"Copyright"}]}}